Organogenesis establishes up to $75M at-the-market equity offering program

Filed August 6, 2026 · Period ending August 6, 2026 · ~1 min read

Key Changes

• high

  Company entered into sales agreement with BTIG and Citizens JMP allowing it to sell Class A common stock from time to time at prevailing market prices, up to $75M aggregate proceeds.

  Item 1.01 verify on EDGAR →
• high

  Sales are discretionary with no obligation to sell any shares; company retains full control over timing, pricing, and volume of any offerings under the program.

  Item 1.01 verify on EDGAR →
• medium

  Sales agents will receive commission of up to 3.0% of gross proceeds from any shares sold, a standard fee structure for at-the-market programs.

  Item 1.01 verify on EDGAR →